Theravance Biopharma Inc (TBPH)

Theravance Biopharma's stock has been impacted by several key events. The failure of the Ampreloxetine Phase 3 CYPRESS study led to a significant stock price drop. The company announced organizational restructuring to reduce costs and focus on YUPELRI, expecting substantial annualized cash flow. Earnings reports for Q3 2025, Q4 2025 and Q1 2026 showed growth in YUPELRI sales and revenue. A Strategic Review Committee is evaluating alternatives to maximize shareholder value.

There is an indication of demand seasonality for Theravance Biopharma's YUPELRI, with Q1 2026 U.S. net sales showing customer demand growth consistent with typical first-quarter seasonality.

Theravance Biopharma is focused on developing and commercializing medicines for specialty respiratory and neurologic diseases. Their main product is YUPELRI, a once-daily nebulized LAMA for COPD, commercialized in collaboration with Viatris Inc. The company previously developed Ampreloxetine for symptomatic neurogenic orthostatic hypotension, but the program was discontinued after disappointing Phase 3 results.

Theravance Biopharma develops and commercializes medicines in the United States and Europe. The company is headquartered in South San Francisco, California, and has a presence in Dublin, Ireland.

Theravance Biopharma's brand reputation has been negatively impacted by the failure of the Phase 3 CYPRESS study for ampreloxetine. This has led to a stock price decline and investigations by law firms regarding potential securities law violations and misleading statements.

Theravance Biopharma has 174 institutional owners and shareholders holding a total of 49,649,068 shares. Major institutional owners include Madison Avenue Partners, LP, Weiss Asset Management LP, Newtyn Management, LLC, BlackRock, Inc., Irenic Capital Management LP, Vanguard Group Inc, D. E. Shaw & Co., Inc., Acadian Asset Management Llc, State Street Corp, and Arrowstreet Capital, Limited Partnership. Eli Samaha is the largest individual shareholder, owning 34.96% of the company, and Glaxosmithkline PLC holds a 18.73% stake.